Addison Biological Laboratory, Inc. announces the approval of the world’s first commercial Moraxella bovoculi vaccine for the prevention of pinkeye in cattle. This USDA conditionally licensed product is the first of this kind. Previously, the only method of prevention against *Moraxella bovoculi* was autogenous services. This vaccine signifies a breakthrough in convenience for the large number of veterinarians and herd owners battling the challenging problem of pinkeye caused by *Moraxella bovoculi*. This product license is conditional; efficacy and potency have not been fully demonstrated.

**From the LEADERS in pinkeye prevention!**

Addison Biological Laboratory, Inc.
www.addisonlabs.com
info@addisonlabs.com
800-331-2530
2016 - 2017
AABP OFFICERS

President-Elect
MIKE D. APLEY
DVM
Manhattan, Kansas

Vice-President
GLENN M. ROGERS
DVM
Aledo, Texas

Past President
JOHN DAVIDSON
DVM
Shiner, Texas

President
MARK J. THOMAS
DVM
Lowville, New York

Executive Vice-President
K. FRED GINGRICH II
DVM
Ashland, Ohio

Directors

District 1
CARIE TELGEN
DVM
Greenwich, New York

District 2
THOMAS B. MASSIE, JR.
DVM
Washington, Virginia

District 3
LEE JONES
DVM
Tifton, Georgia

District 4
GAROLD H. KOESTER
DVM
Cadillac, Michigan

District 5
HUNTER LANG
DVM
Prairie du Sac, Wisconsin

Copyright American Association of Bovine Practitioners; open access distribution.
District 6
VICKIE L. COOPER
DVM
Ames, Iowa

District 7
RODNEY K. CHAPMAN
DVM
Versailles, Missouri

District 8
JOE M. HILLHOUSE
DVM
Panhandle, Texas

District 9
JEFF D. ONDRAK
DVM
Fairbury, Nebraska

District 10
GERARD J. KOENIG
DVM
Tulare, California

District 11
DALE A. MOORE
DVM
Moscow, Idaho

District 12
WAYNE S. SHEWFELT
DVM
Tavistock, Ontario, Canada

District 13
ERIC BEHLKE
DVM
Okotoks, Alberta, Canada

Treasurer
BRYAN D. HALTEMAN
DVM
Turlock, California

Exhibits Chairman
CHARLIE HATCHER
DVM
College Grove, Tennessee

Editor
ROBERT A. SMITH
DVM
Stillwater, Oklahoma

Parliamentarian……………………..Christine B. Navarre, DVM, Baton Rouge, Louisiana
AVMA Delegate……………………………..Brian J. Gerloff, DVM, Marengo, Illinois
Vaccinate with a Newport Laboratories' Custom Made Vaccine and be confident that your herd is vaccinated against the specific disease strains found in your area. Our Custom Made Vaccines can be built to address a specific disease or a combination of diseases. Choose custom made because every situation is different.

Find What You’ve Been Missing @ Newport Laboratories
800-220-2522 | www.newportlabs.com

Custom Made Vaccines are sold exclusively through your veterinarian.

©The Newport Laboratories Logo is a registered trademark of Newport Laboratories, Inc. ©2017 Newport Laboratories, Inc., Worthington, MN All rights reserved. NLRBU065 (10/17)
# Table of Contents

## GENERAL SESSIONS
- Medical error: Knowing (and herding) the elephants  
  John M. Gay ............................................................... 1
- Effects of production practices on *Mannheimia haemolytica*  
  Amelia R. Woolums .................................................. 8
- Facts and fiction regarding anthelmintic efficacies in cattle; an updated assessment  
  T. A. Vazwinski, C. A. Tucker, L. Jones ............................. 11
- Nine months in with the veterinary feed directive: Experiences and what is next  
  Michael D. Apley .......................................................... 16
- Role of the microbiome in respiratory disease  
  Megan C. Niederwerder ................................................. 20
- The planned response to an FMD outbreak is not what it used to be  
  Danielle A. Bickett-Weddle, Molly Lee, Renee Dewell,  
  Kristen Obbink, Mike Sanderson, Christy Hanthorn,  
  James A. Roth ............................................................. 24
- Bovine anaplasmosis: What we know that just ain’t so!  
  Johann F. Coetzee ....................................................... 28
- The future of genetic alteration in food animal production  
  Alison L. Van Eenennaam ................................................ 32

## BEEF SESSIONS
- Does modified-live viral vaccine administration to heifers or cows lack substantial risk?  
  M. Daniel Givens, Benjamin W. Newcomer ................................ 43
- Myth: One oral electrolyte is just as good as another  
  Geoff W. Smith ............................................................ 49
- Myth: All calves are created equal—only selling pounds at weaning  
  S. L. Northcutt, B. Bowman ............................................. 56
- Preconditioning beef calves is an economic "no-brainer"  
  Oliver C. Schunicht ....................................................... 59
- Myth - Veterinarians and nutritionists can NOT work together  
  to collectively bring additive value to feedlot clients  
  M. L. Moy, A. L. Shreck, R. D. Rodermacher ...................... 63
- Critically evaluating alternative cattle handling techniques  
  Nathan Meyer, Grant Dewell, Josh Szasz, Tony Bryant,  
  Casey McMurphy .......................................................... 66

## DAIRY SESSIONS
- Fresh cow metabolic diseases: Old myths and new data  
  Garrett R. Oetzel ......................................................... 70
- Methods of measurement and implications of abnormal  
  calcium concentrations in fresh dairy cows  
  Jessica A. A. McArt, Rafael C. Neves ................................. 81
- Myth: High SCC is always problematic (or is it?)  
  David F. Kelton ............................................................ 85
- Myth: Better to treat too many than not enough  
  Pamela L. Ruegg ........................................................... 89
- Designing protocols/SOPs and monitoring for implementation  
  David A. Rohda ............................................................. 96
- Impact of age on antibiotic distribution and efficacy in calves  
  Danielle A. Mzyk .......................................................... 99
- More is better – Reviewing the science behind duration of antimicrobial therapy  
  Brian V. Lubbers .......................................................... 102
- Common myths in treating calf diarrhea  
  Geoff W. Smith ........................................................... 107
- Myth: "What doesn’t kill you makes you stronger": Early life performance and future implications  
  Joao H. C. Costa ........................................................ 114
- Myth: "Calves forgive and forget" – early socialization and housing effects on performance, health, behavior and cognition*  
  Joao H. C. Costa, Heather W. Neave .................................. 119

## AAASRP SMALL RUMINANTS SESSIONS
- On the farm procedures, anesthesia and analgesia  
  Cindy Wolf ................................................................. 126
- Myth-busting strategies for ovine progressive pneumonia virus (OPPV) control  
  Cindy Wolf ................................................................. 128
- Adding small ruminant reproduction to your practice:  
  Breaking the myth that you need expensive equipment and extensive training  
  Clifford F. Shipley ......................................................... 131
- Small ruminant ophthalmology - The eyes have it  
  Mary C. Smith ............................................................. 136
- Diagnosis and treatment of sheep and goat dyspnea -  
  Small ruminant respiratory diseases  
  Mary C. Smith ............................................................. 140

## PRACTICE MANAGEMENT SESSIONS
- Myth: No way a recent grad can afford to buy a practice  
  Jessica Trichel ............................................................ 144
- Can you sell your practice?  
  David F. McCormick ..................................................... 147
- Early career practice ownership: An older solution to a newer problem  
  Jennifer M. GlAESmann .................................................. 151
- Myth buster: "I can't become a practice owner with debt"  
  Melvin D. Wenger, Gabriel E. Middleton .............................. 155
- Myth: We all know what our clients want and need  
  Dickson (Dick) W. Lewis .................................................. 158
- Utilizing the value proposition in dairy practice  
  Jonathan R. O. Garber ................................................... 162

## STUDENT SESSIONS
- People sometimes lie, but lesions seldom do. Addressing field necropsy and submissions for more useful information  
  Daniel Scruggs ............................................................. 166
- Taking the mystery out of food animal surgery for the new graduate  
  Aubrey N. "Nickie" Baird ................................................. 173

## RESEARCH SUMMARIES
- The effect of Celmanax™ SCP on fecal pathogen shedding, health, and performance of preweaned Holstein dairy calves  
  S. Raabis, T. L. Ollivett ................................................ 177
- Development of a risk assessment tool for prevention of bovine respiratory disease in pre-weaned calves on California dairies  
  G. U. Maier, W. J. Love, B. Karle, S. Dubrovsky, D. Williams,  
  J. Champagne, R. Anderson, J. Stackhouse .......................... 178
• Multi-drug residues and antimicrobial resistance patterns in waste milk from dairy farms in Central California
  P. N. Tempini, S. S. Aly, B. M. Karle, R. V. Pereira ........................................ 179
• Clinical trial of local anesthetic protocols for acute pain associated with caustic paste disbudding in dairy calves
• Comparison of online, hands-on, and a combined approach for teaching cauterization disbudding technique, including administration of a cornual nerve block, to dairy producers
• Using transverse ultrasonography to investigate the impact of antibiotic therapy on the health and performance of preweaned dairy calves
  E. S. Binversie, T. L. Ollivett ........................................ 182
• Randomized clinical trial investigating the effect of a more liberal milk allowance in the dairy after birth on the health and growth of preweaned dairy calves
  W. A. Knauer, S. M. Godden, J. Sorg, S. M. McGuirk ........................................ 183
• The correlation between naturally captured rumen temperature of boluses and morbidity in group housed, preweaned dairy calves
  W. A. Knauer, S. M. Godden ........................................ 184
• A model of foot-and-mouth disease transmission and detection within a U.S. beef feedlot
  A. H. Cabezas, M. W. Sanderson, V. V. Volkova ........................................ 185
• The accuracy of field diagnosis and key diagnostic findings in feedlot cattle diagnosed with acute interstitial pneumonia in southwest Kansas at the time of necropsy
  B. Bennett, E. F. Schwanitz, J. N. Henningson, D. U. Thomson ........................................ 186
• Quantifying the relationship between calving ease and physiological indicators of trauma in beef calves
• A study of enterohemorrhagic Escherichia coli in beef cow-calf herds in Mississippi and Nebraska
  L. G. Schneider, Z. R. Stromberg, G. L. Lewis, R. A. Moxley, D. R. Smith ........................................ 188
• Breeding bulls as a source of BLV transmission
• The effect of different treatments for early lactation hyperketonemia on blood β-hydroxybutyrate, plasma non-esterified fatty acids, glucose, insulin, and glucagon in dairy cattle
  S. Mann, F. A. Leal Yepes, E. Behling-Kelly, J. A. A. McArt ........................................ 190
• Prepartum application of internal teat sealant and/or intramammary amoxicillin on dairy heifers: impact on udder health, survival, and performance
  V. S. Machado, R. C. Bicalho ........................................ 191
• The effects of an oral supplement containing calcium and live yeast on circulating calcium and production of IV lipopolysaccharide infusion in dairy cows
• Evaluating quarter versus composite milk sampling for detection of subclinical intramammary infections
  K. D. Bach, A. Sipka, J. A. A. McArt ........................................ 193
• Use of a data-driven algorithm to guide selective dry-cow therapy
• Investigation of the relationship between bacteria counts, bedding characteristics and bedding management practices with udder health and milk quality on dairy farms: preliminary results
• Effect of oral calcium bolus supplementation on rumination and activity patterns in early lactation dairy cows
• Association of immediate postpartum calcium concentration with clinical diseases, culling, reproduction and milk production in Holstein cows
  R. C. Neves, B. M. Leno, M. D. Curler, M. J. Thomas, T. R. Overton, J. A. A. McArt ........................................ 197
• Rapid typing of Mannheimia haemolytica major genotypes 1 and 2 using MALDI-TOF mass spectrometry
  J. D. Loy, M. L. Clawson ........................................ 198
• Prevalence of multi drug antimicrobial resistance in Mannheimia haemolytica isolated from high-risk stocker cattle at arrival and two weeks after processing
  E. Snyder, B. Credille, R. Berghaus, S. Giguerelle ........................................ 199
• Antimicrobial susceptibility in Mannheimia haemolytica isolated from high-risk stocker cattle after metaphylaxis and treatment
  A. Woolums, B. Karisch, D. R. Smith, J. Blanton, F. Austin, J. Frye, L. Hiott, M. McClelland ........................................ 200
• Prevalence of gastrointestinal nematode resistance to avermectin anthelmintics on beef cattle operations in Georgia
  Kelsey Paras, Melissa George, Sue Howell, James Collins, Bob Storey, Ray Kaplan ........................................ 201
• Economic benefits of diagnostic testing in livestock: Anaplasmosis in cattle
  Thomas L. Marsh ........................................ 202
• Association among genomic breeding values for daughter pregnancy rate and heifer conception rate and estrous characteristics and fertility of Holstein heifers
  Anderson Veronese, Odinei Marques, Rafael Moreira, Anna Belli, Francisco Pellagricano, Ricardo C. Chebel ........................................ 203
• Evaluation of reproductive performance of dairy heifers subjected to two estrus detection systems and treated with two prostaglandin formulations
  A. Veronese, O. Marques, R. Moreira, A. Belli, T. R. Bilby, R. C. Chebel ........................................ 204
• Estrous characteristics of dairy heifers treated at different stages of the estrous cycle with two prostaglandin formulations
  Anderson Veronese, Odinei Marques, Rafael Moreira, Anna Belli, Todd R. Bilby, Ricardo C. Chebel ........................................ 205
• Pregnancy loss attributable to mastitis in primiparous Holstein cows: a matched case-control study
• Comparison of a novel Ovsynch program utilising early pregnancy diagnosis as a measure of performance in Australian pastured based dairy herds
• Accuracy of color flow doppler ultrasonography to diagnose nonpregnancy in dairy cows 21 days after last insemination
  J. Houle, S. Buczinski, J. Dubuc .................. 208
• What veterinarians need to know about producers’ perceptions in order to optimize their role as advisors for key animal care issues in dairy herds
• Evaluating the effect of two hoof trimming techniques on lesion incidence in dairy cattle
  G. Stoddard, N. Cook, S. Wagner, G. Cramer .......... 210
• Study to measure the effect of implanting Holstein steers at various stages of growth and the impact on weight gain and interference with subsequent implants
  J. C. Gawthrop, C. M. McKaig, K. K. Funk, A. C. Budzinski .... 211
• Effects of liver abscess severity and quality grade on meat tenderness and sensory attributes in commercially finished beef cattle fed without tylosin phosphate
  E. J. McCoy, T. G. O’Quinn, E. F. Schwandt, C. D. Reinhardt, D. U. Thomson ........................................... 212
• Genetic comparison of Florida beef cows with and without ovarian follicular dysplasia
  J. Gard, J. Roberts, F. Biase, M. Mansour, J. Wenzel, M. Edmondson, O. Rae, T. Braden ................ ................ 213
• Superovulation and embryo transfer in Wagyu donors and cross-bred recipients: A retrospective analysis of reproductive performance
  G. C. Gomes, D. O. Rae, J. Black, C. A. Risco ........ 214
• Elevated storage temperatures and concentration of large animal pharmaceuticals
  J. D. Ondrak, M. L. Jones, V. R. Fajt, T. P. Mays ........ 215
• Risk factors associated with septic arthritis of the distal interphalangeal joint in beef cattle
• Investigation of a reported increase in clinical disease attributed to anaplasmosis and babesiosis in Costa Rican dairy herds
• Validation of commercial luminometry swabs for enumeration of total bacteria and coliform counts in colostrum feeding equipment
• Risk factors associated with early mortality identified on arrival to a milk-fed veal facility
• Salmonella Heidelberg: An emerging problem in the dairy industry
  D. C. Sockett, N. A. Aulik, K. M. Deering, R. F. Klos, A. M. Valley ................................................................. 219
• Evaluation of four commercial tests for detection of cetiofur in waste milk tank samples
  R. V. Pereira, P. Tempini, M. A. Belmar ............................................................... 220
• Cow- and herd-level prevalence of hypoglycemia in hyperketonemic postpartum dairy cows
  J. Dubuc, S. Buczinski ................................................................. 221
• Assessment of gastrointestinal nematode parasitism in dairy calves housed in calf hutches
  Anna Walker, Ray Kaplan, Kelsey Paras, David Smith, Min Wang, Amelia Woolouns ........................................... 221
• Association between prepartum dry matter intake, net energy balance, and postpartum diseases in dairy cows
• Field trial of two calcium supplements on early lactation health and production in multiparous Holstein cows
  A. R. Domino, H. C. Korzec, J. A. A. McArt .............................................................. 224
• Differential effect of a single dose of oral Ca based on postpartum plasma Ca concentration in Holstein cows
• Assessment of lidocaine local anesthesia and meloxicam analgesia on duration of castration and subsequent feeding and locomotion behavior
  Brian Vander Ley, Stacy Krumme, Pamela Adkins, Dusty Nagy, Cody Dalton ........................................ 226

POSTERS
• Effect of injectable castration administered at feedlot entry on gain performance, behavior, testosterone production, and serum haptoglobin concentration in beef bulls
• A review: Transportation of commercial finished cattle and animal welfare considerations
  S. J. Schwetz, E. F. Schwandt, R. G. Maghirang, D. U. Thomson .......................................................... 228
• Comparing Neospora caninum serology results with pregnancy success and subsequent congenital infection in a South Dakota commercial cow-calf herd
  R. F. Daly, H. C. Krueger, G. A. Perry ......................................................... 229
• Description of the preputial microbiota of bulls using 16S r-DNA profiling
  J. H. Kiziol, S. L. Yingst, A. Ruple, G. K. Hammac, B. Funnell ... 230
• Efficacy of bovine viral diarrhea modified-live virus vaccine to provide fetal protection for BVDV type 1 and 2 virus in cattle
  Jennifer R. DeRoos, Brett Terhaar, G. Allen Bridges ............. 231
• Evaluation of a refugia-based strategy in pastured stocker cattle treated with LongRange®
  Kelsey Paras, Amelia Woolouns, Kris Hubbard, Liesel Schneider, Brandi Karisch, John Blanton .................. 232
• Application of the matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry method to identify Moraxella spp isolated from cattle eyes
  Kara Robbins, Aaron Kickey, Michael L. Clawson, John Dustin Loy ......................................................... 233
• Development of a health index using an automated, chute-side blood leukocyte differential to guide antibiotic treatment at processing
  M. E. Hockett, A. M. Saxton, K. L. Lukasiewicz, J. A. Valles .... 234
• A composition study of a targeted sampling of iodixide family ticks and their pathogen status throughout the Flint Hills region of Kansas
• Retrospective study of retroperitoneal abscess in cattle
  S. Ferrara, A. Desrochers, S. Nichols, D. Francoz, M. Babkine, H. Larde ........................................... 235

• Extended withdrawal time (EWDT) of drugs to prevent residues in food following extra label use
  Pritam K. Kidhu, Ronette Gehring, Lisa A. Tell, Ronald E. Baynes, Danielle A. Mzyk, Jim E. Riviere .............. 236

• Effects of Tri-Lution® on serum volatile fatty acids, electrolytes, and trace mineral status in commercial veal calves
  L.A. Krueger, G.A. Ayangbile ...................................................... 237

• Evaluation of mycobacterium cell wall fraction (MCWF) immune stimulant as antimicrobial alternative following administration to veal calves
  Masic Aleksandar, Keunen Aaron, Milovanovic Aleksandar, Bugarski Dejan, Alkemade Stanley ........................ 239

• Relationship between BCAA and blood pH in diarrheic calves
  K. Tsukano, K. Suzuki, Y. Nishi, S. Sarashina ........................................... 240

• Probiotic therapy as an alternative to antibiotics in calves with moderate diarrhea
  T. Fukuda, K. Tsukano, Y. Nishi, M. Amatatsu, K. Suzuki ................. 241

• Pharmacokinetics and adverse reactions to fentanyl transdermal patches in healthy and hospitalized calves

• Comparison of ionized calcium concentrations using an Abaxis Vetscan iSTAT with a Horiba LAQUAtwin calcium meter in dairy cows fed low, medium, and high calcium DCAD rations and challenged with EGTA
  A.P. Prichard, C.E. Wimmler, P.M. Crump, A.D. Rowson, S.S. Bascom, D.E. Nuzback .................................. 242

• Effect of prepartum energy balance on neutrophil function following pegbovigrastim treatment in periparturient cows
  Scott McDougall, Paul Rapnicki, Stephen LeBlanc, Axel Heiser ......................... 243

• Pegbovigrastim affected gene expression in neutrophils of transition cows indicating increased neutrophil function
  Axel Heiser, Stephen LeBlanc, Paul Rapnicki, Scott McDougall .............. 244

• Induction of hypocalcemia in non-lactating, non-pregnant Holstein cows fed negative DCAD rations with low, medium or high concentrations of calcium
  A.P. Prichard, C.E. Wimmler, P.M. Crump, A.D. Rowson, S.S. Bascom, D.E. Nuzback .............................. 245

AASRP RESEARCH SUMMARIES
• Improved serodiagnosis of CAE and OPP: An investigation of unexpected positives caused by an interfering factor in fresh samples in isolated cases
  S.A. Hines, A. Johnson, A.L. Bronkowski, T.J. Heiniger .......................... 246

• Efficacy of using sex-sorted semen technologies for laparoscopic artificial insemination in a commercial white-tailed deer farm (Odocoileus virginianus)

• Efficacy of ponazuril in weaned feeder lambs with naturally acquired coccidiosis

• Climbing behaviour in lactating dairy goats: The use of a raised platform
  G. Zobel, H. Neave, J. Webster ............................................................ 249

• Characterization of efficacy and animal safety across four caprine disbudding methodologies: heat cauter, clove oil injection, short-term application of caustic paste, and freezing
  K.M. Still Brooks, M. Hempstead, S.T. Millman .................................. 250

• The impact of pregnancy toxemia in goats on the survival rate of newborn kids
  I.M. Andrade, R.D. Bexiga, L.P. Lanas, N. Carolina, M.S. Lima ................ 251

• Effects of seasonality on male white-tailed deer (Odocoileus virginianus) reproductive characteristics

AASRP POSTERS
• Preliminary validation of an indirect ELISA for diagnosis of Johne’s disease in goats
  S.A. Hines, J. Rzepka ................................................................. 253

• Pain responses associated with four caprine disbudding methodologies: heat cauter, clove oil injection, short-term application of caustic paste, and freezing

Advertisers’ Index

Addison Biological Laboratory, Inc. .......................................................... inside front cover
BCF Technology ...................................................................................... 255
Boehringer Ingelheim ............................................................................ 256, back cover
Elanco Animal Health ........................................................................... front of book
Newport Laboratories ........................................................................... front of book
Norbrook Laboratories Limited .................................................................. 27

French translations by Mr. Guy Beauchamp. Revisions by Dr. Emile Bouchard.

Notice to Readers

Articles published in the Proceedings of the American Association of Bovine Practitioners are not peer-reviewed or refereed. All statements, opinions and conclusions contained in articles in the Proceedings are those of the author(s), and are not necessarily those of the American Association of Bovine Practitioners (AABP) unless specifically approved by the AABP Board of Directors.
Fetal protection against bovine viral diarrhea virus type 1 and type 2 challenge<sup>1,2</sup>

DeRoos, J. and B. Terhaar

Study overview

The purpose of this study was to determine whether heifers vaccinated with a combination vaccine, Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza<sub>3</sub>-Respiratory Syncytial Virus Vaccine, Modified Live Virus, *Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona* Bacterin, were protected against the development of persistently infected (PI) calves following exposure to virulent type 1 and type 2 bovine virus diarrhea virus (BVDV).

Exposure of susceptible, pregnant cattle to BVDV early in their pregnancy often results in embryonic death and resorption. Infection of susceptible pregnant cattle with a non-cytopathic (NC) BVDV early in their pregnancy (40 to 125 days) can result in abortion, resorption or the delivery of a PI calf.<sup>3</sup>

Experimental design

- The study was performed at RTI (Rural Technologies Inc.) in cooperation with the South Dakota State University diagnostic laboratory
- All heifers were seronegative to BVDV type 1 and BVDV type 2 and, negative for BVDV PI by skin test via immunohistochemistry
- Heifers were randomized to one of four treatment groups:
  - Group A (vaccinate) — Vaccination with Titanium<sup>®</sup> 5 L5 HB and Type 1 BVDV challenge
  - Group B (control) — Vaccination with a 5-way leptospira HB vaccine and Type 1 BVDV challenge
  - Group C (vaccinate) — Vaccination with Titanium 5 L5 HB and Type 2 BVDV challenge
  - Group D (control) — Vaccination with a 5-way leptospira HB vaccine and Type 2 BVDV challenge

Angus cross heifers (n=104) were enrolled in this study for the vaccination and breeding events. The study investigator and all laboratory personnel were blinded with respect to treatment allocation. Additionally, individuals making the clinical observations were blinded as to the treatment group allocations. The heifers were double ear-tagged and metal ear-tagged then randomly assigned (by using the RAND function in Microsoft EXCEL) to either Treatment Group A, B, C or D.

For inclusion in the trial, the heifers were not pregnant at Study Day (SD) 0 and all animals were shown to be seronegative for BVD type 1 and BVD type 2 (<1:2 serum neutralization titer). Only heifers seronegative for BVD, as described above, and found to be PI-negative by ear notch immunohistochemistry (performed by the Veterinary Diagnostic Laboratory, Iowa State University) were included in the trial.

Heifers in Groups A and C (n=69) were vaccinated with a single 2 mL SQ dose of Titanium 5 L5 HB according to label directions. Heifers in Groups B and D (n=35) were vaccinated with a 2 mL SQ dose of a 5-way leptospira HB according to label directions (Groups B and D).

Heifers were heat synchronized for artificial insemination on Study Day 32.

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Number of Head</th>
<th>Challenge Virus</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>21</td>
<td>BVDV NC type 1</td>
</tr>
<tr>
<td>B</td>
<td>11</td>
<td>BVDV NC type 1</td>
</tr>
<tr>
<td>C</td>
<td>24</td>
<td>BVDV NC type 2</td>
</tr>
<tr>
<td>D</td>
<td>11</td>
<td>BVDV NC type 2</td>
</tr>
</tbody>
</table>
Heifers were confirmed pregnant by ultrasound on Study Day 122 and were also palpated prior to challenge. At the time of the ultrasound, 67 heifers were confirmed pregnant and at the correct fetal gestational age to be enrolled in the challenge phase of the trial. Heifers were between 71 and 90 days of gestation on the day of challenge. Heifers in Groups A and B received an intranasal challenge of virulent NC BVDV type 1 (strain BJ). Heifers in Groups C and D received an intranasal challenge of virulent NC BVDV type 2 (strain PA 131). Heifers in all groups were examined daily for visual signs of abortion.

Between 71 and 81 days post-challenge, heifers were slaughtered and fetuses were harvested. Heart, blood, spleen, thymus and cerebellum were collected from each fetus for challenge virus isolation. PI fetuses were defined by viral isolation from tissues sampled at fetal harvest or at necropsy. Also, any abortion, resorption or open heifer following challenge was considered as a PI fetus unless definitively demonstrated to be unrelated to the challenge organism.

The individual animal was included at the experimental unit. Differences between the treatment groups were deemed statistically significant if $P < 0.05$. The primary outcome variable (percent of PI fetuses) was evaluated using Fisher’s exact test. If a treatment effect was detected, the prevented fraction (PF) and the 95% confidence interval around the PF were estimated.

### Results

The BVDV type 1 challenge was given to treatment groups A and B. BVDV type 1 was isolated from nine out of 11 (81.8%) fetuses from the BVD negative control (Group B) heifers. In the BVD vaccine group A, 2 out of 21 (9.5%) fetuses were BVDV positive. There was a significant decrease in the number of BVDV PI fetuses in the vaccine group. The PF from the statistical analysis was 0.8889.

The BVDV type 2 challenge was given to treatment groups C and D. BVDV type 2 was isolated from 11 out of 11 (100%) fetuses from the BVD negative control (Group D) heifers. BVDV type 2 was isolated from two out of 24 (8.3%) fetuses from the BVD vaccinated (Group C) heifers. There was a significant decrease in the number of BVDV PI fetuses in the vaccine group. The PF from the statistical analysis was 0.9167.

### Percentage of PI Fetuses

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Challenge Virus</th>
<th>% PI Fetuses</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Titanium 5 L5 HB</td>
<td>BVDV NC type 1</td>
<td>9.5</td>
</tr>
<tr>
<td>B Control</td>
<td>BVDV NC type 1</td>
<td>81.8</td>
</tr>
<tr>
<td>C Titanium 5 L5 HB</td>
<td>BVDV NC type 2</td>
<td>8.3</td>
</tr>
<tr>
<td>D Control</td>
<td>BVDV NC type 2</td>
<td>100</td>
</tr>
</tbody>
</table>

